|
CEP135 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.56130000039667E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.92109999919543E-08 |
| Normal-vs-Stage2 |
2.18519999872768E-08 |
| Normal-vs-Stage3 |
6.42349999857572E-08 |
| Normal-vs-Stage4 |
1.28749999550593E-08 |
| Stage1-vs-Stage2 |
2.239500E-02 |
| Stage1-vs-Stage3 |
4.871600E-02 |
| Stage1-vs-Stage4 |
1.202210E-02 |
| Stage2-vs-Stage3 |
4.133800E-01 |
| Stage2-vs-Stage4 |
8.697000E-01 |
| Stage3-vs-Stage4 |
3.153000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.06910003072613E-09 |
| Normal-vs-AfricanAmerican |
6.788600E-04 |
| Normal-vs-Asian |
1.020270E-04 |
| Caucasian-vs-AfricanAmerican |
9.633200E-01 |
| Caucasian-vs-Asian |
5.592200E-01 |
| AfricanAmerican-vs-Asian |
6.492000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.97369999735508E-08 |
| Normal-vs-Female |
2.05380000006805E-07 |
| Male-vs-Female |
8.329400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.67519999996857E-06 |
| Normal-vs-Age(41-60Yrs) |
3.4202999987798E-08 |
| Normal-vs-Age(61-80Yrs) |
1.18010001770585E-09 |
| Normal-vs-Age(81-100Yrs) |
2.340000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.779500E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.597600E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.803600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.724000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.431800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.691800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.568400E-02 |
| Classical-VS-Follicular |
2.656700E-03 |
| Classical-VS-Other |
7.162800E-01 |
| Classical-VS-Normal |
1.59585999999212E-05 |
| Tall-VS-Follicular |
9.084400E-01 |
| Tall-VS-Other |
5.979800E-01 |
| Tall-VS-Normal |
1.25340000001195E-06 |
| Follicular-VS-Other |
5.568400E-01 |
| Follicular-VS-Normal |
1.77729997385967E-09 |
| Other-VS-Normal |
4.161900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.07480000244698E-08 |
| Normal-vs-N1 |
1.75556999999493E-05 |
| N0-vs-N1 |
6.301600E-01 |
|
|
